Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 71 - 80 out of 107

AMIA Response Letter to Centers for Disease Control and Prevention (CDC)

September 7, 2012

Dear Dr. Buehler,

On behalf of AMIA (the American Medical Informatics Association), I am pleased to submit these comments in response to the above-referenced request for comments. AMIA thanks the Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC) Public Health Surveillance and Informatics […]

AMIA Comments Submitted RE: ICD-10 Delay

May 17, 2012

Re: 45 CFR Part 162 [CMS–0040–P] RIN 0938–AQ13Administrative Simplification: Adoption of a Standard for a Unique Health Plan Identifier; Addition to the National Provider Identifier Requirements; and a Change to the Compliance Date for ICD–10–CM and ICD–10–PCS Medical Data Code Sets

AMIA participates in Coalition for an Informed Patient Identity Integrity Solution

November 29, 2011

Along with several other organizations, AMIA is participating in the Coalition for an Informed Patient Identity Integrity Solution. The Coalition is working to delete prohibiting language from the fiscal year 2012 Labor, HHS Appropriations bill, and to substitute language that would have HHS conduct a study of the health information […]

AMIA Comments on NIST Usability Guidance

November 10, 2011

AMIA acknowledged NIST’s efforts to highlight the importance of usability testing for electronic health records (EHRs) through its issuance of the proposed guidance. AMIA expressed concerns about several aspects of the draft guidance including the following: a limited and narrow identification of EHR users; the need to consider more comprehensive […]

AMIA Comments on FDA Mobile Medical Apps Draft Guidance

October 19, 2011

AMIA recently issued comments in response to a U.S. Food and Drug Administration (FDA) draft guidance on mobile medical applications. In the comments, AMIA president Ted Shortliffe noted, among other things, the need for additional clarification, definitions, terms, and terminology in the guidance. Click below to read AMIA's full comments.